Advertisement

Chemotherapy of Ewing Sarcoma

  • Stefano Ferrari
  • Emanuela PalmeriniEmail author
Chapter
  • 253 Downloads

Abstract

Ewing sarcoma (ES) shares with osteosarcoma similarities in the strategy of treatment.

Keywords

Multimodal treatment Neoadjuvant chemotherapy Chemotherapy-induced necrosis Clinical studies High-dose chemotherapy 

References

  1. 1.
    ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii100–9.Google Scholar
  2. 2.
    Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.CrossRefGoogle Scholar
  3. 3.
    Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18:3108–14.CrossRefGoogle Scholar
  4. 4.
    Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4–11.CrossRefGoogle Scholar
  5. 5.
    Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(15):2536–41.CrossRefGoogle Scholar
  6. 6.
    Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(33):4148–54.CrossRefGoogle Scholar
  7. 7.
    Ferrari S, Sundby Hall K, Luksch R, et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011;22(5):1221–7.CrossRefGoogle Scholar
  8. 8.
    Whelan J, Le Deley MC, Dirksen U, et al. Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): results of EURO-EWING 99-R2 randomized trial (EE99R2Loc). J Clin Oncol. 2016;34(15_Suppl):11000.CrossRefGoogle Scholar
  9. 9.
    Cangir A, Vietti TJ, Gehan EA, et al. Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer. 1990;66:887–93.CrossRefGoogle Scholar
  10. 10.
    Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol. 2003;21(18):3423–30.CrossRefGoogle Scholar
  11. 11.
    Luksch R, Tienghi A, Hall KS, et al. Primary metastatic Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol. 2012;23(11):2970–6.CrossRefGoogle Scholar
  12. 12.
    Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284–91.CrossRefGoogle Scholar
  13. 13.
    Dirksen U, Le Deley MC, Brennan B, et al. Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul). J Clin Oncol. 2016;34(15_Suppl):11001.CrossRefGoogle Scholar
  14. 14.
    Bacci G, Longhi A, Ferrari S, et al. Pattern of relapse in 290 patients with nonmetastatic Ewing’s sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol. 2006;32(9):974–9.CrossRefGoogle Scholar
  15. 15.
    Briccoli A, Rocca M, Ferrari S, Mercuri M, Ferrari C, Bacci G. Surgery for lung metastases in Ewing’s sarcoma of bone. Eur J Surg Oncol. 2004;30(1):63–7.CrossRefGoogle Scholar
  16. 16.
    Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006;47(6):795–800.CrossRefGoogle Scholar
  17. 17.
    Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48(2):132–9.CrossRefGoogle Scholar
  18. 18.
    Palmerini E, Jones RL, Setola E, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol. 2018;13:1–7.Google Scholar
  19. 19.
    Ferrari S, del Prever AB, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009;52(5):581–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Chemotherapy UnitIRCCS Istituto Ortopedico RizzoliBolognaItaly
  2. 2.Department of Experimental, Diagnostic and Specialty Medicine (DIMES)University of BolognaBolognaItaly

Personalised recommendations